Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print].
A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.
Bensinger WI et al. Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.211. [Epub ahead of print].
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P et al. Biol Blood Marrow Transplant. 2015 Aug 29. pii: S1083-8791(15)00574-1. doi: 10.1016/j.bbmt.2015.08.026. [Epub ahead of print].
Reduced relapse rate in upfront tandem autologous/reduced intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression free and not of overall survival.
Lokhorst HM et al. Haematologica. 2015 Sep 4. pii: haematol.2015.128728. [Epub ahead of print].
Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
de Waal EG et al. Br J Haematol. 2015 Sep 11. doi: 10.1111/bjh.13653. [Epub ahead of print].
Comment on “Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma”.
Harrison SJ et al. Haematologica. 2015 Sep;100(9):e379. doi: 10.3324/haematol.2015.128470.
Bendamustine, Lenalidomide, And Dexamethasone (BRD) Is Highly Effective With Durable Responses In Relapsed Multiple Myeloma.
Kumar S et al. Am J Hematol. 2015 Sep 2. doi: 10.1002/ajh.24181. [Epub ahead of print].